Climb Bio, Inc. (CLYM)
Automate Your Wheel Strategy on CLYM
With Tiblio's Option Bot, you can configure your own wheel strategy including CLYM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLYM
- Rev/Share 0.0
- Book/Share 2.7486
- PB 0.8899
- Debt/Equity 0.0034
- CurrentRatio 14.0828
- ROIC -0.3022
- MktCap 165750989.0
- FreeCF/Share -0.5879
- PFCF -4.1714
- PE -3.5355
- Debt/Assets 0.0033
- DivYield 0
- ROE -0.231
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CLYM | Robert W. Baird | -- | Outperform | -- | $9 | Aug. 15, 2025 |
| Initiation | CLYM | Oppenheimer | -- | Outperform | -- | $10 | June 6, 2025 |
| Initiation | CLYM | BTIG Research | -- | Buy | -- | $7 | May 22, 2025 |
News
Climb Bio, Inc. (CLYM)'s Technical Outlook is Bright After Key Golden Cross
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Climb Bio, Inc. (CLYM) could be a good stock pick from a technical perspective. CLYM recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
Read More
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Read More
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
Read More
Climb Bio to Present at Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
Read More
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.
Read More
About Climb Bio, Inc. (CLYM)
- IPO Date
- Website https://eliemtx.com
- Industry Biotechnology
- CEO Aoife M. Brennan BAO, BCh, MB, MMSc
- Employees 17